Targeting CD38 in Relapsed/Refractory Multiple Myeloma
EP. 1: Factors To Be Considered When Treating RRMM
December 24th 2019
EP. 2: Importance of Molecular Characterization When Treating RRMM
December 24th 2019
EP. 3: OPTIMISMM Trial: Pomalidomide in RRMM
December 24th 2019
EP. 4: Rationale for using CD38-Targeted Antibody in RRMM
December 24th 2019
EP. 5: MOA and Safety Profile of Isatuximab from the ICARIA Study
December 24th 2019
EP. 6: Sequencing of Antibodies to Treat Daratumumab Resistance
December 24th 2019
EP. 7: Emerging Therapies to Treat RRMM
December 24th 2019
